N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients

Scientific Reports
Xiaofen ZongXiaogang Chen

Abstract

It is unclear whether N-acetylaspartate (NAA) depletions documented in schizophrenia patients might be due to the disease progression or medications. Here we investigated longitudinal NAA changes in drug-naïve first-episode patients (FEP) who are relatively free from chronicity. Forty-two drug-naïve FEP and 38 controls were enrolled in this study to explore the effect of 8-week risperidone monotherapy on NAA. All spectra were obtained from the medial prefrontal cortex (MPFC) on a 3.0 T MRI and analyzed with LCModel. At baseline, patients presented no significant differences in NAA (P = 0.084) or NAA/Cr + Pcr (P = 0.500) compared to controls; NAA levels were negatively correlated with PANSS total scores (P = 0.001) and WCST-PE (P = 0.041). After treatment, patients demonstrated significant reductions of NAA (P < 0.001) and NAA/Cr + Pcr (P < 0.001), and significant improvement in PANSS-P (P < 0.001) and PANSS-G (P < 0.001) symptoms. We detected no significant correlations between NAA alterations and PANSS-P (P = 0.679) or PANSS-G (P = 0.668) symptom changes; nor did NAA/Cr + Pcr changes with alterations in PANSS-P (P = 0.677) and PANSS-G (P = 0.616). This is the first evidence that short-term risperidone treatment induces an acut...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Dec 1, 1986·Radiology·P R Luyten, J A den Hollander
May 1, 1993·Annals of Neurology·C BurkhardtW D Parker
Nov 1, 1995·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·N De StefanoD L Arnold
Oct 1, 1996·Brain : a Journal of Neurology·Y NagahamaJ Kimura
Apr 30, 1999·Neuropharmacology·S BalijepalliV Ravindranath
May 29, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·C DautryP Hantraye
Mar 2, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Dieter F BrausFritz A Henn
Feb 6, 2007·Progress in Neurobiology·John R MoffettAryan M A Namboodiri
Oct 2, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·V MolinaM Desco
Dec 21, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan R BustilloJohn Lauriello
Jul 23, 2008·Molecular Psychiatry·E S LutkenhoffT D Cannon
Nov 18, 2009·Molecular Psychiatry·J R BustilloJ Lauriello
Jan 18, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L Fredrik JarskogJeffrey A Lieberman

❮ Previous
Next ❯

Citations

Sep 4, 2015·Clinical Neuroradiology·H LanfermannP Raab
Dec 21, 2016·Neuroscience Bulletin·Mao-Lin HuJin-Song Tang
Oct 17, 2018·NPJ Schizophrenia·Richard NewtonBenedicto Crespo-Facorro

❮ Previous
Next ❯

Software Mentioned

LCModel
SPSS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here